Market Overview

UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014

Share:
Related INFI
Stifel Talks 5 Biotech Stocks
Deutsche Sees Cancer Treatment Home Run At Infinity Pharmaceuticals

In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Infinity Pharmaceuticals (NASDAQ: INFI) from Outperform to Neutral, but reiterated the $20.00 price target.

In the report, Credit Suisse noted, “We are downgrading INFI to Neutral because (1) limited clinical data is expected in 2014, (2) an increasingly complex competitive landscape, which we think is evolving to favor BTK inhibitors and ABT-199 over PI3K inhibitors; and (3) risk of class effect safety issues or drug specific safety issues, although initial concerns over infections and liver enzymes seem to have cooled down.”

Infinity Pharmaceuticals closed on Wednesday at $13.31.

Latest Ratings for INFI

DateFirmActionFromTo
May 2015Deutsche BankInitiates Coverage onBuy
Jan 2015Morgan StanleyDowngradesOverweightEqualweight
Dec 2014Credit SuisseUpgradesNeutralOutperform

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Credit Suisse Jason KantorAnalyst Color Downgrades Analyst Ratings

 

Related Articles (INFI)

Get Benzinga's Newsletters